

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 28, 2007

Signature: *Li Hsien Rin-Laures*

(Li-Hsien Rin-Laures, M.D.)

Docket No.: 31075/40037
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Zankel et al.

Application No.: 10/812,849

Confirmation No.: 3684

Filed: March 30, 2004

Art Unit: 1649

For: MEGALIN-BASED DELIVERY OF
THERAPEUTIC COMPOUNDS TO THE
BRAIN AND OTHER TISSUES

Examiner: Daniel Kolker

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other

Application No.: 10/812,849



Docket No.: 31075/40037

material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 31075/40037.

Dated: February 28, 2007

Respectfully submitted,

By *Li Hsien Rin-Laures*

Li-Hsien Rin-Laures, M.D.

Registration No.: 33,547

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/812,849-Conf. #3684
				Filing Date	March 30, 2004
				First Named Inventor	Todd C. Zankel
				Art Unit	1649
				Examiner Name	Daniel Kolker
Sheet	1	of	2	Attorney Docket Number	31075/40037

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-2003/0129186-A1	07-10-2003	Beliveau et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C64	Anderson et al., "Differential Binding of Ligands to the Apolipoprotein E Receptor 2," <i>Biochemistry</i> , 42:9355-9364 (2003).	
	C65	Anderson et al., "Dominant Thermodynamic Role of the Third Independent Receptor Binding Site in the Receptor-Associated Protein RAP," <i>Biochemistry</i> , 40:15408-15417 (2001).	
	C66	Anderson et al., "Identification of the Minimal Functional Unit in the Low Density Lipoprotein Receptor-related Protein for Binding the Receptor-associated Protein (RAP)," <i>J. Biol. Chem.</i> , 275(28):21017-21024 (2000).	
	C67	Bajari et al., "A Minimal Binding Domain of the Low Density Lipoprotein Receptor Family," <i>Biol. Chem.</i> , 379:1053-1062 (1998).	
	C68	Bickel et al., "Pharmacologic Effects in Vivo in Brain by Vector-mediated Peptide Drug Delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 90:2618-2622 (1993).	
	C69	Bogan et al., "Anatomy of Hot Spots in Protein Interfaces," <i>J. Mol. Biol.</i> , 280:1-9 (1998).	
	C70	Bu, "The Roles of Receptor-Associated Protein (RAP) as a Molecular Chaperone for Members of the LDL Receptor Family," <i>Int. Rev. Cytol.</i> , 209:79-116 (2001).	
	C71	Clackson et al., "A Hot Spot of Binding Energy in a Hormone-receptor Interface," <i>Science</i> , 267:383-386 (1995).	
	C72	DeLano, "Unraveling Hot Spots in Binding Interfaces: Progress and Challenges," <i>Curr. Opin. Struct. Biol.</i> , 12:14-20 (2002).	
	C73	Dwyer et al., "High Affinity RNase S-Peptide Variants Obtained by Phage Display Have a Novel 'Hot-Spot' of Binding Energy," <i>Biochemistry</i> , 40:13491-13500 (2001).	
	C74	Fisher et al., "Structure of an LDLR-RAP Complex Reveals a General Mode for Ligand Recognition by Lipoprotein Receptors," <i>Molecular Cell</i> , 22:277-283 (2006).	
	C75	Gao et al., "Structure-based Method for Analyzing Protein-Protein Interfaces," <i>J. Mol. Model</i> , 10:4-54 (2004).	
	C76	Halperin et al., "Protein-Protein Interactions: Coupling of Structurally Conserved Residues and of Hot Spots Across Interfaces. Implications for Docking," <i>Structure</i> , 12:1027-1038 (2004).	
	C77	Horn et al., "Molecular Analysis of Ligand Binding to the Second Cluster of Complement-type	
Examiner Signature		Date Considered	

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/812,849-Conf. #3684
				Filing Date	March 30, 2004
				First Named Inventor	Todd C. Zankel
				Art Unit	1649
				Examiner Name	Daniel Kolker
Sheet	2	of	2	Attorney Docket Number	31075/40037

		Repeats of the Low Density Lipoprotein Receptor-related Protein," <i>J. Biol. Chem.</i> , 272(21):13608-13613 (1997).	
	C78	Jensen et al., "Binding Site Structure of One LRP-RAP Complex: Implications for a Common Ligand-Receptor Binding Motif," <i>J. Mol. Biol.</i> , 362:700-716 (2006).	
	C79	Kounnas et al., "The 39-kDa Receptor-Associated Protein Interacts with Two Members of the Low Density Lipoprotein Receptor Family, α 2-Macroglobulin Receptor and Glycoprotein 330," <i>J. Biol. Chem.</i> , 267(29):21162-21166 (1992).	
	C80	Lee et al., "RAP Uses a Histidine Switch to Regulate its Interaction with LRP in the ER and Golgi," <i>Mol. Cell</i> , 22:423-430 (2006).0.	
	C81	Li et al., "Magnitude of the Hydrophobic Effect at Central Versus Peripheral Sites in Protein-Protein Interfaces," <i>Structure</i> , 13:297-307 (2005).	
	C82	Lisi et al., "Preferential Megalin-mediated Transcytosis of Low-hormonogenic Thyroglobulin: a Control Mechanism for Thyroid Hormone Release," <i>Proc. Natl. Acad. Sci. USA</i> , 100(25):14858-14863 (2003).	
	C83	McCormick et al., "Independent and Cooperative Roles of N-Glycans and Molecular Chaperones in the Folding and Disulfide Bond Formation of the Low-Density Lipoprotein (LDL) Receptor-Related Protein," <i>Biochemistry</i> , 44:5794-5803 (2005).	
	C84	Migliorini et al., "Allosteric Modulation of Ligand Binding to Low Density Lipoprotein Receptor-related Protein by the Receptor-associated Protein Requires Critical Lysine Residues within its Carboxyl-terminal Domain," <i>J. Biol. Chem.</i> , 278(20):17986-17992 (2003).	
	C85	Neels et al., "The Second and Fourth Cluster of Class a Cysteine-rich Repeats of the Low Density Lipoprotein Receptor-related Protein Share Ligand-binding Properties," <i>J. Biol. Chem.</i> , 274(44):31305-31311 (1999).	
	C86	Obermoeller et al., "Differential Functions of Triplicated Repeats Suggest Two Independent Roles for the Receptor-Associated Protein as a Molecular Chaperone," <i>J. Biol. Chem.</i> , 272(16):10761-10768 (1997).	
	C87	Prince et al., "Lipoprotein Receptor Binding, Cellular Uptake, and Lysosomal Delivery of Fusions Between the Receptor-Associated Protein (RAP) and α -L-Iduronidase or Acid α -Glucosidase," <i>J. Biol. Chem.</i> , 279(33):35037-35046 (2004).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--